Clinical Cardiology Alert – January 1, 2024
January 1, 2024
View Issues
-
Percutaneous Coronary Intervention vs. Placebo for Stable Angina Patients
In this randomized trial of patients with stable angina and objective evidence of ischemia, percutaneous coronary intervention resulted in a significant reduction in angina compared to a placebo procedure.
-
Apixaban vs. Aspirin for Subclinical Atrial Fibrillation
A randomized controlled trial of apixaban vs. low-dose aspirin therapy for subclinical atrial fibrillation detected by implanted electrophysiologic devices showed that apixaban is associated with fewer strokes, but more major bleeding episodes compared to aspirin.
-
Atorvastatin vs. Rosuvastatin in Patients with Coronary Artery Disease
A large trial of moderate doses of rosuvastatin vs. atorvastatin in patients with coronary artery disease has shown that both drugs are equivalent at reducing major adverse cardiovascular and cerebral events, but rosuvastatin is associated with higher rates of new- onset diabetes and cataract surgery.
-
Anti-Ischemic Therapy for Microvascular Angina
A small, invasive study of coronary microvascular disease patients has shown that those with a coronary flow reserve < 2.5 may benefit from anti-ischemic therapy.
-
A New Intervention Criterion for Ascending Aortic Aneurysm
A large retrospective study from the Yale University Aortic Institute database of unoperated patients with ascending thoracic aneurysms has shown that the risk of an adverse aortic event rises significantly at 5.0 cm to 5.4 cm in maximum diameter and supports moving the guideline for surgical intervention from 5.5 cm to 5.0 cm.